The effects of sertraline on blood lipids, glucose, insulin and HBA1C levels: A prospective clinical trial on depressive patients

Murat Kesim, Ahmet Tiryaki, Mine Kadioglu, Efnan Muci, Nuri Ihsan Kalyoncu, Ersin Yaris, Murat Kesim, Ahmet Tiryaki, Mine Kadioglu, Efnan Muci, Nuri Ihsan Kalyoncu, Ersin Yaris

Abstract

Background: In this study, we aimed to investigate the possible effects of sertraline on blood glucose and lipid levels as risk factors for cardiovascular disease in depressive patients.

Methods: Eight male and twelve female depressive patients, diagnosed according to DSM-IV criteria, were included in this study. The subjects aged 19-50 years, did not smoke, and had normal body mass index (BMI), homeostasis model assessment-estimated insulin resistance (HOMA-IR) values, blood pressure, blood glucose, insulin and lipid levels. Sertraline therapy (50 mg/day) was started. Patients with diabetes mellitus, heart disease, pregnancy, and those taking other drugs were excluded from the study. Blood glucose, insulin, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), and triglyceride values were measured in patients before, and at the 4(th), 8(th) and 12(th) weeks after treatment with sertraline. Moreover, HbA1C levels were measured at the beginning and at the end of the treatment (at 12(th) weeks).

Results: There were no significant differences in physical examination (blood pressure, BMI, body weight, height, waist circumference) and laboratory findings (glucose, HDL-C, LDL-C, HOMA-IR and HbA1C levels) at the 12(th) week after of treatment with sertraline compared to pretreatment values. However, insulin levels at the 4(th), 8(th) and 12(th) weeks significantly increased compared with pretreatment values. Likewise, triglyceride levels at the 8(th) and 12(th) weeks significantly increased compared with pretreatment values.

Conclusions: Sertraline-treated patients have to be followed up for blood insulin and triglyceride levels. In addition, their treatment plan needs to be adjusted as necessary to prevent possible metabolic changes.

Keywords: Glucose; HbA1C; Insulin; Lipid; Sertraline.

Conflict of interest statement

Conflict of Interests Authors have no conflict of interests.

Figures

Figure 1
Figure 1
Pretreatment and post-treatment blood glucose levels at the 4th, 8th and 12th weeks of sertraline treatment *: Compared with pretreatment values (p

Figure 2

Pretreatment and post-treatment blood insulin…

Figure 2

Pretreatment and post-treatment blood insulin levels at the 4 th , 8 th…

Figure 2
Pretreatment and post-treatment blood insulin levels at the 4th, 8th and 12th weeks of sertraline treatment *: Compared with pretreatment values (p

Figure 3

Pretreatment and post-treatment blood HDL-C,…

Figure 3

Pretreatment and post-treatment blood HDL-C, LDL-C and triglyceride levels at the 4 th…

Figure 3
Pretreatment and post-treatment blood HDL-C, LDL-C and triglyceride levels at the 4th, 8th and 12th weeks of sertraline treatment *: Compared with pretreatment value (p

Figure 4

Pretreatment and post-treatment blood HbA1C…

Figure 4

Pretreatment and post-treatment blood HbA1C levels at the 12 th week of sertraline…

Figure 4
Pretreatment and post-treatment blood HbA1C levels at the 12th week of sertraline treatment *: Compared with pretreatment values (p
Similar articles
Cited by
References
    1. Rubin RR, Gaussoin SA, Peyrot M, DiLillo V, Miller K, Wadden TA, et al. Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia. 2010;53(8):1581–9. - PMC - PubMed
    1. Whang W, Shimbo D, Kronish IM, Duvall WL, Julien H, Iyer P, et al. Depressive symptoms and all-cause mortality in unstable angina pectoris (from the Coronary Psychosocial Evaluation Studies [COPES]) Am J Cardiol. 2010;106(8):1104–7. - PMC - PubMed
    1. Davidson KW, Korin MR. Depression and cardiovascular disease: selected findings, controversies, and clinical implications from 2009. Cleve Clin J Med. 2010;77(Suppl 3):S20–S26. - PMC - PubMed
    1. Glassman A. Depression and cardiovascular disease. Pharmacopsychiatry. 2008;41(6):221–5. - PubMed
    1. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, et al. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med. 2005;67(5):703–6. - PubMed
Show all 21 references
LinkOut - more resources
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 2
Figure 2
Pretreatment and post-treatment blood insulin levels at the 4th, 8th and 12th weeks of sertraline treatment *: Compared with pretreatment values (p

Figure 3

Pretreatment and post-treatment blood HDL-C,…

Figure 3

Pretreatment and post-treatment blood HDL-C, LDL-C and triglyceride levels at the 4 th…

Figure 3
Pretreatment and post-treatment blood HDL-C, LDL-C and triglyceride levels at the 4th, 8th and 12th weeks of sertraline treatment *: Compared with pretreatment value (p

Figure 4

Pretreatment and post-treatment blood HbA1C…

Figure 4

Pretreatment and post-treatment blood HbA1C levels at the 12 th week of sertraline…

Figure 4
Pretreatment and post-treatment blood HbA1C levels at the 12th week of sertraline treatment *: Compared with pretreatment values (p
Similar articles
Cited by
References
    1. Rubin RR, Gaussoin SA, Peyrot M, DiLillo V, Miller K, Wadden TA, et al. Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia. 2010;53(8):1581–9. - PMC - PubMed
    1. Whang W, Shimbo D, Kronish IM, Duvall WL, Julien H, Iyer P, et al. Depressive symptoms and all-cause mortality in unstable angina pectoris (from the Coronary Psychosocial Evaluation Studies [COPES]) Am J Cardiol. 2010;106(8):1104–7. - PMC - PubMed
    1. Davidson KW, Korin MR. Depression and cardiovascular disease: selected findings, controversies, and clinical implications from 2009. Cleve Clin J Med. 2010;77(Suppl 3):S20–S26. - PMC - PubMed
    1. Glassman A. Depression and cardiovascular disease. Pharmacopsychiatry. 2008;41(6):221–5. - PubMed
    1. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, et al. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med. 2005;67(5):703–6. - PubMed
Show all 21 references
LinkOut - more resources
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 3
Figure 3
Pretreatment and post-treatment blood HDL-C, LDL-C and triglyceride levels at the 4th, 8th and 12th weeks of sertraline treatment *: Compared with pretreatment value (p

Figure 4

Pretreatment and post-treatment blood HbA1C…

Figure 4

Pretreatment and post-treatment blood HbA1C levels at the 12 th week of sertraline…

Figure 4
Pretreatment and post-treatment blood HbA1C levels at the 12th week of sertraline treatment *: Compared with pretreatment values (p
Similar articles
Cited by
References
    1. Rubin RR, Gaussoin SA, Peyrot M, DiLillo V, Miller K, Wadden TA, et al. Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia. 2010;53(8):1581–9. - PMC - PubMed
    1. Whang W, Shimbo D, Kronish IM, Duvall WL, Julien H, Iyer P, et al. Depressive symptoms and all-cause mortality in unstable angina pectoris (from the Coronary Psychosocial Evaluation Studies [COPES]) Am J Cardiol. 2010;106(8):1104–7. - PMC - PubMed
    1. Davidson KW, Korin MR. Depression and cardiovascular disease: selected findings, controversies, and clinical implications from 2009. Cleve Clin J Med. 2010;77(Suppl 3):S20–S26. - PMC - PubMed
    1. Glassman A. Depression and cardiovascular disease. Pharmacopsychiatry. 2008;41(6):221–5. - PubMed
    1. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, et al. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med. 2005;67(5):703–6. - PubMed
Show all 21 references
LinkOut - more resources
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 4
Figure 4
Pretreatment and post-treatment blood HbA1C levels at the 12th week of sertraline treatment *: Compared with pretreatment values (p

References

    1. Rubin RR, Gaussoin SA, Peyrot M, DiLillo V, Miller K, Wadden TA, et al. Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia. 2010;53(8):1581–9.
    1. Whang W, Shimbo D, Kronish IM, Duvall WL, Julien H, Iyer P, et al. Depressive symptoms and all-cause mortality in unstable angina pectoris (from the Coronary Psychosocial Evaluation Studies [COPES]) Am J Cardiol. 2010;106(8):1104–7.
    1. Davidson KW, Korin MR. Depression and cardiovascular disease: selected findings, controversies, and clinical implications from 2009. Cleve Clin J Med. 2010;77(Suppl 3):S20–S26.
    1. Glassman A. Depression and cardiovascular disease. Pharmacopsychiatry. 2008;41(6):221–5.
    1. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, et al. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med. 2005;67(5):703–6.
    1. Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van GL. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res. 1996;4(4):391–6.
    1. Ghaeli P, Shahsavand E, Mesbahi M, Kamkar MZ, Sadeghi M, Dashti-Khavidaki S. Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol. 2004;24(4):386–8.
    1. Derijks HJ, Janknegt R, Heerdink ER, De Koning FH, Krekels MM, Looij BJ, et al. Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study. J Clin Psychopharmacol. 2009;29(4):405–8.
    1. Raeder MB, Bjelland I, Emil VS, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry. 2006;67(12):1974–82.
    1. Wei F, Crain AL, Whitebird RR, Godlevsky OV, O’Connor PJ. Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study. CNS Drugs. 2009;23(10):857–65.
    1. Teitelbaum M. Severe hypertriglyceridemia secondary to venlafaxine and fluoxetine. Psychosomatics. 2001;42(5):440–1.
    1. Herran A, Ramirez ML, Carrera M, Garcia-Unzueta MT, Sierra-Biddle D, Rodriguez-Cabo B, et al. Panic disorder, treatment with selective serotonin reuptake inhibitors, and cholesterol levels. J Clin Psychopharmacol. 2006;26(5):538–40.
    1. Erenmemisoglu A, Ozdogan UK, Saraymen R, Tutus A. Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. J Pharm Pharmacol. 1999;51(6):741–3.
    1. Gomez R, Huber J, Tombini G, Barros HMT. Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Brazilian Journal of Medical and Biological Research. 2001;34(1):57–64.
    1. Gomez R, Huber J, Lhullier F, Barros HM. Plasma insulin levels are increased by sertraline in rats under oral glucose overload. Braz J Med Biol Res. 2001;34(12):1569–72.
    1. Pollak PT, Mukherjee SD, Fraser AD. Sertraline-induced hypoglycemia. Ann Pharmacother. 2001;35(11):1371–4.
    1. Sansone RA, Sansone LA. Sertraline-induced hyperglycemia: case report. Int J Psychiatry Med. 2003;33(1):103–5.
    1. Paulmann N, Grohmann M, Voigt JP, Bert B, Vowinckel J, Bader M, et al. Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS Biol. 2009;7(10):e1000229.
    1. Lautt WW, Ming Z, Legare DJ. Attenuation of age- and sucrose-induced insulin resistance and syndrome X by a synergistic antioxidant cocktail: the AMIS syndrome and HISS hypothesis. Can J Physiol Pharmacol. 2010;88(3):313–23.
    1. Sadri P, Reid MA, Afonso RA, Schafer J, Legare DJ, Paula MM, et al. Meal-induced insulin sensitization in conscious and anaesthetized rat models comparing liquid mixed meal with glucose and sucrose. Br J Nutr. 2006;95(2):288–95.
    1. Patarrao RS, Lautt WW, Afonso RA, Ribeiro RT, Guarino MP, Fernandes AB, et al. Meal-induced insulin sensitization and its parasympathetic regulation in humans. Can J Physiol Pharmacol. 2008;86(12):880–8.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe